A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea
ConditionObstructive Sleep Apnea of Adult
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorMayo Clinic
About this trial
Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.
Eligibility criteria
Qualifiers
BMI ≤40 kg/m2
Not a current smoker or tobacco user
Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study
On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), depression, acid reflux (such as antacids or proton pump inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
Disqualifiers
Vulnerable study population will be excluded
Presence of chronic kidney disease (creatinine >2.5 mg/dL) and/or active cancers
Pregnancy
Anemic (hemoglobin <12 g/dL for men and <11 g/dL for women)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
120 Participants
are grouped into 2 trial groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov